188 related articles for article (PubMed ID: 37713484)
1. DUX4-r exerts a neomorphic activity that depends on GTF2I in acute lymphoblastic leukemia.
Campolungo D; Salomé M; Biferali B; Tascini AS; Gabellini D
Sci Adv; 2023 Sep; 9(37):eadi3771. PubMed ID: 37713484
[TBL] [Abstract][Full Text] [Related]
2. Deregulation of DUX4 and ERG in acute lymphoblastic leukemia.
Zhang J; McCastlain K; Yoshihara H; Xu B; Chang Y; Churchman ML; Wu G; Li Y; Wei L; Iacobucci I; Liu Y; Qu C; Wen J; Edmonson M; Payne-Turner D; Kaufmann KB; Takayanagi SI; Wienholds E; Waanders E; Ntziachristos P; Bakogianni S; Wang J; Aifantis I; Roberts KG; Ma J; Song G; Easton J; Mulder HL; Chen X; Newman S; Ma X; Rusch M; Gupta P; Boggs K; Vadodaria B; Dalton J; Liu Y; Valentine ML; Ding L; Lu C; Fulton RS; Fulton L; Tabib Y; Ochoa K; Devidas M; Pei D; Cheng C; Yang J; Evans WE; Relling MV; Pui CH; Jeha S; Harvey RC; Chen IL; Willman CL; Marcucci G; Bloomfield CD; Kohlschmidt J; Mrózek K; Paietta E; Tallman MS; Stock W; Foster MC; Racevskis J; Rowe JM; Luger S; Kornblau SM; Shurtleff SA; Raimondi SC; Mardis ER; Wilson RK; Dick JE; Hunger SP; Loh ML; Downing JR; Mullighan CG;
Nat Genet; 2016 Dec; 48(12):1481-1489. PubMed ID: 27776115
[TBL] [Abstract][Full Text] [Related]
3.
Zaliova M; Potuckova E; Hovorkova L; Musilova A; Winkowska L; Fiser K; Stuchly J; Mejstrikova E; Starkova J; Zuna J; Stary J; Trka J
Haematologica; 2019 Jul; 104(7):1407-1416. PubMed ID: 30630977
[No Abstract] [Full Text] [Related]
4. DNA crosslinking and recombination-activating genes 1/2 (RAG1/2) are required for oncogenic splicing in acute lymphoblastic leukemia.
Zhang H; Cheng N; Li Z; Bai L; Fang C; Li Y; Zhang W; Dong X; Jiang M; Liang Y; Zhang S; Mi J; Zhu J; Zhang Y; Chen SJ; Zhao Y; Weng XQ; Hu W; Chen Z; Huang J; Meng G
Cancer Commun (Lond); 2021 Nov; 41(11):1116-1136. PubMed ID: 34699692
[TBL] [Abstract][Full Text] [Related]
5. N-terminus DUX4-immunohistochemistry is a reliable methodology for the diagnosis of DUX4-fused B-lymphoblastic leukemia/lymphoma (N-terminus DUX4 IHC for DUX4-fused B-ALL).
Siegele BJ; Stemmer-Rachamimov AO; Lilljebjorn H; Fioretos T; Winters AC; Dal Cin P; Treece A; Gaskell A; Nardi V
Genes Chromosomes Cancer; 2022 Aug; 61(8):449-458. PubMed ID: 35218117
[TBL] [Abstract][Full Text] [Related]
6. Emerging molecular subtypes and therapies in acute lymphoblastic leukemia.
Davis K; Sheikh T; Aggarwal N
Semin Diagn Pathol; 2023 May; 40(3):202-215. PubMed ID: 37120350
[TBL] [Abstract][Full Text] [Related]
7. Transcription factor TFII-I fine tunes innate properties of B lymphocytes.
Singh A; Kaileh M; De S; Mazan-Mamczarz K; Bayarsaihan D; Sen R; Roy AL
Front Immunol; 2023; 14():1067459. PubMed ID: 36756127
[TBL] [Abstract][Full Text] [Related]
8. Transcription factor 12-mediated self-feedback regulatory mechanism is required in DUX4 fusion leukaemia.
Li Z; Jiang M; Wang J; Zhuo Z; Zhang S; Tan Y; Hu W; Zhang H; Meng G
Clin Transl Med; 2023 Dec; 13(12):e1514. PubMed ID: 38115701
[TBL] [Abstract][Full Text] [Related]
9. CD371 cell surface expression: a unique feature of
Schinnerl D; Mejstrikova E; Schumich A; Zaliova M; Fortschegger K; Nebral K; Attarbaschi A; Fiser K; Kauer MO; Popitsch N; Haslinger S; Inthal A; Buldini B; Basso G; Bourquin JP; Gaipa G; Brüggemann M; Feuerstein T; Maurer-Granofszky M; Panzer-Grümayer R; Trka J; Mann G; Haas OA; Hrusak O; Dworzak MN; Strehl S
Haematologica; 2019 Aug; 104(8):e352-e355. PubMed ID: 30705095
[No Abstract] [Full Text] [Related]
10.
Tarrini G; Ciabatti E; Pacini S; Galimberti S; Petrini I
Anticancer Res; 2017 Oct; 37(10):5459-5462. PubMed ID: 28982856
[TBL] [Abstract][Full Text] [Related]
11. Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults.
Yasuda T; Tsuzuki S; Kawazu M; Hayakawa F; Kojima S; Ueno T; Imoto N; Kohsaka S; Kunita A; Doi K; Sakura T; Yujiri T; Kondo E; Fujimaki K; Ueda Y; Aoyama Y; Ohtake S; Takita J; Sai E; Taniwaki M; Kurokawa M; Morishita S; Fukayama M; Kiyoi H; Miyazaki Y; Naoe T; Mano H
Nat Genet; 2016 May; 48(5):569-74. PubMed ID: 27019113
[TBL] [Abstract][Full Text] [Related]
12. Structural basis of DUX4/IGH-driven transactivation.
Dong X; Zhang W; Wu H; Huang J; Zhang M; Wang P; Zhang H; Chen Z; Chen SJ; Meng G
Leukemia; 2018 Jun; 32(6):1466-1476. PubMed ID: 29572508
[TBL] [Abstract][Full Text] [Related]
13. Immunoglobulin and T cell receptor gene rearrangement patterns in acute lymphoblastic leukemia are less mature in adults than in children: implications for selection of PCR targets for detection of minimal residual disease.
Szczepański T; Langerak AW; Wolvers-Tettero IL; Ossenkoppele GJ; Verhoef G; Stul M; Petersen EJ; de Bruijn MA; van't Veer MB; van Dongen JJ
Leukemia; 1998 Jul; 12(7):1081-8. PubMed ID: 9665194
[TBL] [Abstract][Full Text] [Related]
14. Distinct clinical characteristics of DUX4- and PAX5-altered childhood B-lymphoblastic leukemia.
Li Z; Lee SHR; Chin WHN; Lu Y; Jiang N; Lim EH; Coustan-Smith E; Chiew KH; Oh BLZ; Koh GS; Chen Z; Kham SKY; Quah TC; Lin HP; Tan AM; Ariffin H; Yang JJ; Yeoh AE
Blood Adv; 2021 Dec; 5(23):5226-5238. PubMed ID: 34547766
[TBL] [Abstract][Full Text] [Related]
15. Profiling chromatin accessibility in pediatric acute lymphoblastic leukemia identifies subtype-specific chromatin landscapes and gene regulatory networks.
Diedrich JD; Dong Q; Ferguson DC; Bergeron BP; Autry RJ; Qian M; Yang W; Smith C; Papizan JB; Connelly JP; Hagiwara K; Crews KR; Pruett-Miller SM; Pui CH; Yang JJ; Relling MV; Evans WE; Savic D
Leukemia; 2021 Nov; 35(11):3078-3091. PubMed ID: 33714976
[TBL] [Abstract][Full Text] [Related]
16. CIC-DUX4 Chromatin Profiling Reveals New Epigenetic Dependencies and Actionable Therapeutic Targets in CIC-Rearranged Sarcomas.
Bakaric A; Cironi L; Praz V; Sanalkumar R; Broye LC; Favre-Bulle K; Letovanec I; Digklia A; Renella R; Stamenkovic I; Ott CJ; Nakamura T; Antonescu CR; Rivera MN; Riggi N
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38275898
[TBL] [Abstract][Full Text] [Related]
17. Frequency and outcome of pediatric acute lymphoblastic leukemia with ZNF384 gene rearrangements including a novel translocation resulting in an ARID1B/ZNF384 gene fusion.
Shago M; Abla O; Hitzler J; Weitzman S; Abdelhaleem M
Pediatr Blood Cancer; 2016 Nov; 63(11):1915-21. PubMed ID: 27392123
[TBL] [Abstract][Full Text] [Related]
18. CN470 is a BET/CBP/p300 multi-bromodomain inhibitor and has an anti-tumor activity against MLL-rearranged acute lymphoblastic leukemia.
Imayoshi N; Yoshioka M; Tanaka K; Yang SM; Akahane K; Toda Y; Hosogi S; Inukai T; Okada S; Maloney DJ; Nakahata T; Takita J; Kato I; Ashihara E
Biochem Biophys Res Commun; 2022 Jan; 590():49-54. PubMed ID: 34971957
[TBL] [Abstract][Full Text] [Related]
19. Transcription factor abnormalities in B-ALL leukemogenesis and treatment.
Yin H; Wang J; Tan Y; Jiang M; Zhang H; Meng G
Trends Cancer; 2023 Oct; 9(10):855-870. PubMed ID: 37407363
[TBL] [Abstract][Full Text] [Related]
20. Glycoproteome remodeling in MLL-rearranged B-cell precursor acute lymphoblastic leukemia.
Oliveira T; Zhang M; Joo EJ; Abdel-Azim H; Chen CW; Yang L; Chou CH; Qin X; Chen J; Alagesan K; Almeida A; Jacob F; Packer NH; von Itzstein M; Heisterkamp N; Kolarich D
Theranostics; 2021; 11(19):9519-9537. PubMed ID: 34646384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
